Suppr超能文献

乳腺癌:环状 RNA 介导临床前模型中的疗效。

Breast Cancer: Circular RNAs Mediating Efficacy in Preclinical Models.

机构信息

Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany

Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.

出版信息

Cancer Genomics Proteomics. 2023 May-Jun;20(3):222-238. doi: 10.21873/cgp.20377.

Abstract

In order to identify new targets and treatment modalities for breast cancer, we searched the literature for circular RNAs (circRNAs) with efficacy in preclinical breast cancer-related in vivo models. From our search, we identified 26 up-regulated and six down-regulated circRNAs which mediate efficacy in breast cancer-related preclinical in vivo models. We discuss reconstitution and inhibition of the identified circRNAs, as well as druggability and validation of the targets identified in the context of chemoresistance, inhibition of proliferation and metastasis. Pathways driven by suppressors of cytokines and high-mobility group proteins, nuclear factor B and Hippo signaling emerged as important drivers of tumor growth and metastasis. The role of trefoil factor-1 with respect to metastasis of estrogen receptor-positive breast cancer also merits further investigation. In addition, mucin 19 has emerged as an unexplored target for treatment of breast cancer.

摘要

为了确定乳腺癌的新靶点和治疗方法,我们在文献中搜索了在临床前乳腺癌相关动物模型中具有疗效的环状 RNA(circRNA)。在我们的研究中,发现了 26 个上调和 6 个下调的 circRNA,它们在乳腺癌相关的临床前动物模型中具有疗效。我们讨论了鉴定出的 circRNA 的重建和抑制,以及药物靶标在化疗耐药、增殖和转移抑制方面的验证。细胞因子和高迁移率族蛋白、核因子 B 和 Hippo 信号通路的抑制剂所驱动的通路被认为是肿瘤生长和转移的重要驱动因素。三叶因子 1 与雌激素受体阳性乳腺癌转移的关系也值得进一步研究。此外,粘蛋白 19 已成为治疗乳腺癌的一个未经探索的靶点。

相似文献

1
Breast Cancer: Circular RNAs Mediating Efficacy in Preclinical Models.
Cancer Genomics Proteomics. 2023 May-Jun;20(3):222-238. doi: 10.21873/cgp.20377.
2
Circular RNAs With Efficacy in Preclinical and Models of Esophageal Squamous Cell Carcinoma.
Cancer Genomics Proteomics. 2022 May-Jun;19(3):283-298. doi: 10.21873/cgp.20320.
3
Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical Models.
Cancer Genomics Proteomics. 2023 Mar-Apr;20(2):117-131. doi: 10.21873/cgp.20368.
4
Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in Preclinical Models.
Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):500-521. doi: 10.21873/cgp.20401.
5
Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.
Cancer Genomics Proteomics. 2023 Dec;20(6suppl):646-668. doi: 10.21873/cgp.20413.
6
Circular RNA-0001283 Suppresses Breast Cancer Proliferation and Invasion via MiR-187/HIPK3 Axis.
Med Sci Monit. 2020 Feb 18;26:e921502. doi: 10.12659/MSM.921502.
7
[Differences in expression profiles of circular RNA between luminal breast cancer cells and normal breast cells].
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(8):1014-1019. doi: 10.3969/j.issn.1673-4254.2018.08.19.
8
CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia.
Cancer Genomics Proteomics. 2024 Mar-Apr;21(2):118-136. doi: 10.21873/cgp.20434.
9
[Differences in circRNA expression profiles between HER-2-positive breast cancer cells and normal mammary epithelial cells].
Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):331-337. doi: 10.3760/cma.j.issn.0253-3766.2019.05.003.
10
Circular RNA hsa_circRNA_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibition of COL1A1.
J Cell Mol Med. 2020 Feb;24(3):2189-2201. doi: 10.1111/jcmm.14875. Epub 2020 Jan 19.

引用本文的文献

1
Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification.
Cancer Genomics Proteomics. 2025 Sep-Oct;22(5):654-682. doi: 10.21873/cgp.20528.
2
circEFR3A promotes breast cancer progression by sponging miR-590-3p to upregulate androgen receptor expression.
Oncol Lett. 2025 Jul 17;30(3):446. doi: 10.3892/ol.2025.15192. eCollection 2025 Sep.
3
Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):136-165. doi: 10.21873/cgp.20494.
4
Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in Preclinical Models.
Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):500-521. doi: 10.21873/cgp.20401.

本文引用的文献

1
Eukaryotic Initiation Factor 4A-3: A Review of Its Physiological Role and Involvement in Oncogenesis.
Front Oncol. 2021 Aug 11;11:712045. doi: 10.3389/fonc.2021.712045. eCollection 2021.
2
Circ_0085495 knockdown reduces adriamycin resistance in breast cancer through miR-873-5p/integrin β1 axis.
Anticancer Drugs. 2022 Jan 1;33(1):e166-e177. doi: 10.1097/CAD.0000000000001174.
3
E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer.
Exp Biol Med (Maywood). 2021 Oct;246(19):2057-2071. doi: 10.1177/15353702211035693. Epub 2021 Aug 9.
5
Circ_0008673 regulates breast cancer malignancy by miR-153-3p/CFL2 axis.
Arch Gynecol Obstet. 2022 Jan;305(1):223-232. doi: 10.1007/s00404-021-06149-w. Epub 2021 Jul 29.
6
Circular RNA circ-MMP11 Contributes to Lapatinib Resistance of Breast Cancer Cells by Regulating the miR-153-3p/ANLN Axis.
Front Oncol. 2021 Jul 6;11:639961. doi: 10.3389/fonc.2021.639961. eCollection 2021.
8
CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis.
Cancer Cell Int. 2021 Jul 19;21(1):384. doi: 10.1186/s12935-021-02088-3.
10
Hsa_circ_0001982 promotes the progression of breast cancer through miR-1287-5p/MUC19 axis under hypoxia.
World J Surg Oncol. 2021 Jun 3;19(1):161. doi: 10.1186/s12957-021-02273-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验